Featured Articles

CEL-SCI Corporation asserted that it was extending the expiration date of its Series DD and Series EE warrants to July 1, 2018. The Series DD and Series EE warrants were issued on…
Read More...

Hong Kong based investment firm, PacBridge Capital Partners has committed to invest C$12,000,000 in Contextual Genomics, leading Canadian Cancer genomics company headquartered in…
Read More...

Pfizer asserted that that the Committee for Medicinal products for Human use of the European Medicines Agency has adopted positive opinions extending marketing authorizations in the EU…
Read More...

AstraZeneca asserted that the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the…
Read More...

Merck and Viralytics claimed that the companies have ventured into a definitive agreement that enumerates Merck's acquisition of Viralytics emphasizing on oncolytic immunotherapy…
Read More...

Evidenced-based dual diagnosis treatment facility, Chiron Recovery executed a MAT program for the treatment of opioid addiction. Addiction is a chronic disease and just like other…
Read More...

Global pharmaceutical company, Glenmark Pharmaceuticals ventured into an exclusive agreement with Sam Chun Dang Pharma. Co. Ltd. (SCD) to develop, manufacture and market a portfolio of…
Read More...

GSK presented at the Center for Disease Control and Prevention Advisory Committee on Immunization Practices meeting that FLUARIX QUADRIVALENT exhibited 63.2% efficacy against moderate…
Read More...

Company dedicated to enhancing healthcare through earlier detection of cancer, Imagion Biosystems, asserted the appointment of Farideh Bischoff, PhD as the Vice President of Clinical…
Read More...

KAND567 is an orally available small molecule that blocks CX3CR1, the Fractalkine receptor. It is to be noted that Fractalkine receptor is an immunomodulating factor termed as …
Read More...

Maker of innovative, needle-free injection technology,  PharmaJet asserted venturing into a global license agreement with  Genexine, for the development and commercialization of DNA…
Read More...

The Janssen Pharmaceutical Companies of Johnson and Johnson asserted extrapolation of data that exemplified 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at…
Read More...

GenePOC asserted the launch of GenePOC GBS LB assay which is implied to be in its home market for the revogene instrument. The revogene is an automated stand-alone instrument that…
Read More...

Anew Era TMS is a provider of transcranial magnetic stimulation TMS for treating individuals with medication-resistant depression and skin disorders. TMS offers and extends a safe and…
Read More...

Non-profit organization, Aeras committed to developing vaccines against TB declared results from breakthrough Clinical Trial aiding evidence that TB Vaccines could forbid sustained…
Read More...

Roche and Flatiron Health asserted that the two partners have ventured into a definitive agreement enumerating that Roche will acquire all shares of Flatiron  Health from an existing…
Read More...

AbbVie asserted results from the double-blinded extension phase of the Phase 2 CELEST Study, exhibiting that many patients treated with upadacitinib who attained clinical response after…
Read More...

Novartis declared additional results from the SCULPTURE study marking that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx exhibited zero impact of skin…
Read More...

Teva Pharmaceutical Industries asserted the commercial availability of QVAR RediHaler Inhalation Aerosol to patients in both 40 mcg and 80 mcg strengths by prescription in the U.S QVAR…
Read More...

Banyan Biomarkers asserted that the U.S FDA has extended De Novo request for the commercialization of Banyan BTI Brain Trauma Indicator), an in vitro diagnostic blood test to aid in the…
Read More...